OOIR: Observatory of International Research

Papers

(The H4-Index of Haemophilia is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A	73
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US	42
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	42
European principles of care for women and girls with inherited bleeding disorders	38
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC	37
Genetic causes of haemophilia in women and girls	34
Low immunogenicity of emicizumab in persons with haemophilia A	34
Emicizumab state‐of‐the‐art update	33
Evidence of a disability paradox in patient‐reported outcomes in haemophilia	31
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management	30
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)	29
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A	28
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature	28
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study	27
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data	27
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	25
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	24
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery	23
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis	22
The Function of extravascular coagulation factor IX in haemostasis	21
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	21
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making	21